Dana Investment Advisors Inc. Acquires Shares of 21,237 LivaNova PLC $LIVN

Dana Investment Advisors Inc. bought a new position in LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 21,237 shares of the company’s stock, valued at approximately $1,112,000.

A number of other institutional investors have also made changes to their positions in the company. Mitsubishi UFJ Asset Management UK Ltd. lifted its stake in LivaNova by 80.0% during the third quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 4,500 shares of the company’s stock worth $236,000 after purchasing an additional 2,000 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of LivaNova by 31.9% during the third quarter. PNC Financial Services Group Inc. now owns 1,901 shares of the company’s stock worth $100,000 after purchasing an additional 460 shares during the period. LSV Asset Management lifted its position in shares of LivaNova by 25.4% in the 3rd quarter. LSV Asset Management now owns 674,610 shares of the company’s stock worth $35,336,000 after buying an additional 136,600 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in shares of LivaNova by 168.1% in the 3rd quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company’s stock worth $1,421,000 after buying an additional 17,007 shares during the last quarter. Finally, Allianz Asset Management GmbH acquired a new position in shares of LivaNova in the 3rd quarter valued at about $7,687,000. 97.64% of the stock is currently owned by institutional investors.

Trending Headlines about LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 beat — LivaNova reported Q4 revenue of $360.9M (up ~12% YoY) and adjusted EPS of $0.86, topping consensus on both top and bottom lines; management highlighted organic growth across core businesses. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Raised FY2026 EPS guidance — management issued EPS guidance of $4.15–$4.25 versus consensus near $3.90, signaling stronger-than-expected margin and earnings leverage for the year. Revenue guidance was roughly in line with consensus (~$1.5B). LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Analyst upgrade/price-target lift — Needham raised its price target to $81 and kept a Buy rating, providing additional analyst support for the rally. Livanova (LIVN) PT Raised to $81 at Needham
• Positive Sentiment: Short interest fell materially in February (down ~16.6%), lowering potential short-squeeze risk and reducing bearish positioning. (Data released by exchanges; summary in earnings coverage.)
• Neutral Sentiment: New data partnership — LivaNova announced a data partnership with Orrum that could enhance its cardiac-care analytics and reimbursement narrative, but the commercial impact is still speculative. Could LivaNova’s (LIVN) Data Partnership With Orrum Quietly Reshape Its Cardiac Care Narrative?
• Neutral Sentiment: Earnings materials and call transcript released — slide deck and full call transcript are available for investors to review execution details and product cadence. LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Margin profile and GAAP metrics — despite adjusted EPS beats, LivaNova still shows pressure on GAAP margins (company-reported net margin metrics), which investors will watch as guidance is executed. LivaNova Q4 Earnings Snapshot

LivaNova Price Performance

Shares of LIVN opened at $71.00 on Friday. LivaNova PLC has a one year low of $32.48 and a one year high of $71.92. The stock’s fifty day moving average is $64.59 and its 200-day moving average is $58.90. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.12 and a current ratio of 1.36. The firm has a market capitalization of $3.88 billion, a price-to-earnings ratio of -15.92 and a beta of 0.97.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The firm had revenue of $360.86 million during the quarter, compared to analyst estimates of $354.31 million. During the same quarter in the prior year, the firm posted $0.81 EPS. LivaNova’s revenue was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Equities analysts anticipate that LivaNova PLC will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on LIVN shares. Robert W. Baird set a $75.00 price objective on shares of LivaNova in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Mizuho raised their price target on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. KeyCorp initiated coverage on LivaNova in a research note on Friday, December 19th. They set an “overweight” rating and a $81.00 price objective for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a research report on Thursday, February 19th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $74.11.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.